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In Brief
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GSK3b inhibitors in the squamous
subtype of PDAC. This study provides an
important proof of concept that
chromatin accessibility can be used to
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potential therapeutic utility.ll
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https://doi.org/10.1016/j.celrep.2020.107625SUMMARYPancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad lin-
eages referred to as classical (pancreatic) and squamous. We find that these two subtypes are driven by
distinct metabolic phenotypes. Loss of genes that drive endodermal lineage specification, HNF4A and
GATA6, switchmetabolic profiles from classical (pancreatic) to predominantly squamous,with glycogen syn-
thase kinase 3 beta (GSK3b) a key regulator of glycolysis. Pharmacological inhibition of GSK3b results in se-
lective sensitivity in the squamous subtype; however, a subset of these squamous patient-derived cell lines
(PDCLs) acquires rapid drug tolerance. Using chromatin accessibility maps, we demonstrate that the squa-
mous subtype can be further classified using chromatin accessibility to predict responsiveness and toler-
ance to GSK3b inhibitors. Our findings demonstrate that distinct patterns of chromatin accessibility can
be used to identify patient subgroups that are indistinguishable by gene expression profiles, highlighting
the utility of chromatin-based biomarkers for patient selection in the treatment of PDAC.Cell Reports 31, 107625, May 12, 2020 ª 2020 The Author(s). 1
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The prognosis for patients suffering from pancreatic ductal
adenocarcinoma (PDAC) is extremely poor, with less than 8%
of patients surviving for more than 5 years after diagnosis.
PDAC is defined by a complex and heterogeneous mutational
landscape with a handful of highly recurrent mutations in well-
described cancer genes and a plethora of low-frequency events
associated with genes of often unknown function (Bailey et al.,
2016; Biankin et al., 2012; Humphris et al., 2017; Waddell
et al., 2015; Witkiewicz et al., 2015). Establishing which of these
events drive tumor progression and/or survival has proved chal-
lenging. One obstacle is our limited ability to stratify patients for
targeted therapy and a lack of biomarkers to direct clinical deci-
sion-making (Biankin et al., 2015). Improved patient stratification
andmore effective approaches to therapy are urgently needed to
improve outcomes for pancreatic cancer.
Recent integratomic studies have demonstrated that PDAC is
composed of two major transcriptomic subtypes, namely, clas-
sical (pancreatic) and squamous, which are characterized by
distinct mutations, gene expression profiles, and prognosis
(Bailey et al., 2016; Collisson et al., 2011, 2019; Moffitt et al.,
2015). The classical (pancreatic) subtype is characterized by
differentiated duct cell marker expression and a favorable prog-
nosis, whereas the squamous subtype is associated with gene
silencing of endoderm specification genes, such as HNF1A,
HNF4A, and GATA6; metabolic reprogramming; and poor clin-
ical outcome. Importantly, the dynamic changes in gene expres-
sion observed between the classical (pancreatic) and squamous
subtypes are driven by alterations in the epigenetic landscape
(Bailey et al., 2016; Lomberk et al., 2018; Somerville et al.,
2018). The squamous subtype is further typified by mutations
in members of the COMPASS-like complex that regulate histone
methylation, including KDM6A, MLL2, and MLL3 (Andricovich
et al., 2018; Bailey et al., 2016).
Gene programs that characterize PDAC squamous tumors
include those involved in hypoxia response, metabolic reprog-
ramming, and autophagy (Bailey et al., 2016), suggesting that
metabolic targeting in this subtype may be effective. Extensive
work by others has shown that metabolic rewiring is central to
PDAC’s ability to survive within a nutrient- and oxygen-depleted
tumor microenvironment (Chini et al., 2014; Commisso et al.,
2013; Guillaumond et al., 2013; Son et al., 2013). Moreover,
themajor oncogenic driver in PDAC, KRAS, along with the selec-
tive pressure of a hypoxic tumor environment can promotemeta-
bolic rewiring through stimulating glycolysis (Ying et al., 2012)
and autophagy (Yang and Kimmelman, 2011, 2014). These
studies also highlight the intrinsic metabolic plasticity of pancre-
atic cancer cells, which may, in part, explain the lack of signifi-
cant therapeutic benefit of metabolic targeting (Baek et al.,
2014; Boudreau et al., 2016; Sancho et al., 2015). Furthermore,
recent data now suggest that plasticity exists between subtypes.
For example, the targeted inhibition of Colony-Stimulating Fac-
tor 1 Receptor (CSF1R) in LSL-KrasG12D/+;Trp53fl/+;Pdx1-Cre
(KPC) genetically engineered mouse models (GEMMs) results
in a profound reprogramming of tumor cell-intrinsic pathways
from predominantly squamous to classical (pancreatic) (Candido
et al., 2018). Likewise, MET Proto-Oncogene, Receptor Tyro-2 Cell Reports 31, 107625, May 12, 2020sone Kinase (MET) inhibition in squamous PDAC induces a tran-
scriptional switch toward classical (pancreatic) associated gene
programs, in particular those driven by GATA6 (Lomberk et al.,
2018). Therefore, metabolic plasticity or adaptation and ther-
apy-induced subtype switching may represent important impli-
cations for disease progression, drug resistance, and the devel-
opment of subtype-specific therapies. Deciphering the
transcriptional regulatory networks underpinning subtype plas-
ticity has the potential to identify therapeutic vulnerabilities and
nodes of therapy evasion.
To address these questions, we used a set of 48 early-pas-
sage PDAC patient-derived cell lines (PDCLs) that provide an
isogenic and experimentally tractable system for developing
and validating subtype-dependent therapeutic vulnerabilities.
We show that PDCLs recapitulate major metabolic transcrip-
tional profiles observed in bulk PDAC tissue, and that plasticity
exists between PDAC subtypes. Specifically, HNF4A and
GATA6 loss in a classical (progenitor) background can drive a
switch toward squamous-associated metabolic reprograming
events and identify GSK3b as a driver of glycolysis. Pharmaco-
logical inhibition of GSK3b showed selective sensitivity in the
squamous subtype; however, a subset of these squamous
PDCLs acquire rapid drug tolerance. Using assay for transpo-
sase-accessible chromatin sequencing (ATAC-seq) analysis,
we show that the squamous subtype separates into two distinct
chromatin subgroups with unique chromatin accessibility and
promoter usage. We demonstrate that the drug-tolerant squa-
mous subgroup has access to an amplified WNT signaling pro-
gram via application of both intronic and distal promoter usage.
Using both transcriptomic and chromatin landscape profiles, we
provide a model system to predict PDAC responders and non-
responders to subtype-specific therapeutic vulnerabilities.
RESULTS
PDAC PDCLs Recapitulate Metabolic Profiles Observed
in PDAC Bulk Tumor Tissue
We have previously demonstrated that transcriptional networks
involved in energy source generation differ substantially between
the classical (pancreatic) and squamous subtypes (Bailey et al.,
2016). Comparative analysis of bulk tumor and PDCL transcrip-
tomes demonstrated that PDCLs faithfully recapitulate the two
broad PDAC transcriptomic subtypes observed in bulk tumor
samples (Figures S1A and S2A; Table S1). Importantly, several
gene programs representing key metabolic processes were
highly preserved in PDCLs and, in keeping with our previous an-
alyses, exhibited subtype-specific enrichment (Figures 1A–1C;
Table S1). Squamous PDCLs were enriched for transcripts regu-
lating mammalian Target Of Rapamycin (mTOR) signaling and
glycolysis, in particular AKT3 and Enolase 1 (ENO1), respec-
tively, whereas the classical (pancreatic) PDCLs were enriched
for fatty acid biosynthesis and elongation processes, such as
the gene encoding the rate-limiting enzyme in fatty acid biosyn-
thesis acetyl-coenzyme A (CoA) carboxylase b (ACACB) and the
beta-oxidation pathway enzyme hydroxyacyl-CoA dehydroge-
nase (HADH). Liquid chromatography-mass spectrometry (LC-
MS) analysis supported these findings and revealed subtype-
specific differences in metabolite pools, with an enrichment of
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OPEN ACCESSglycolysis intermediates in squamous PDCLs (Figure 1H; Table
S2). Similarly, squamous PDCLs were associated with increased
extracellular acidification rates (ECARs; indicative of lactate
accumulation) and decreased oxygen consumption compared
with classical (pancreatic) PDCLs (Figures 1E–1G, and S1B; Ta-
ble S3). Functional assessment of glucose uptake and lactate
production further supported this analysis, with increased
glucose uptake and lactate production indicative of increased
glycolytic flux in squamous PDCLs (Figure 1D; Table S3). Collec-
tively, these data suggest that squamous PDCLs are highly cata-
bolic and utilize glycolysis as their main source of energy.
Glycolytic gene expression, glucose uptake, and lactate
secretion are increased in homozygote KRASG12D/G12D mutated
lung cancer cells relative to KRASG12D/WT heterozygous (Kerr
et al., 2016); therefore, the difference in glycolytic activity be-
tween classical (pancreatic) and squamous PDCLs may be a
consequence of difference in KRAS copy number. However,
DNA sequencing analysis established that KRASG12D heterozy-
gotes and homozygotes were present across both subtypes
(Figure S1C; Table S4). Enhanced glycolysis is a well-estab-
lished phenotype of cancer that is typically associated with
increased growth demands and/or compensatory adaptation
to mitochondrial defects (Lin et al., 2012; Vander Heiden et al.,
2009). Mitochondrial gene mutations were similar across sub-
types (Figure S1D), suggesting that mitochondrial mutations
were not driving a switch toward glycolysis, and growth rates
were not significantly different between subtypes (Figures S1E
and S1F). These data suggest that either differential KRAS de-
pendency (Singh et al., 2009) exists between classical (pancre-
atic) and squamous PDCLs, or a further genetic or epigenetic
event is required to switch cells toward a squamous-like meta-
bolic preference for glycolysis.
Loss ofHNF4AorGATA6 inClassical (Pancreatic) PDCLs
Recapitulates Transcriptional Profiles Associated with
the Squamous Subtype
Wepreviously established that the squamous subtype is charac-
terized by hypermethylation and concordant downregulation ofFigure 1. Metabolic Differences Between Squamous and Classical (Pa
(A) Heatmap of pathways and molecular processes involved in cancer metabolism
and glycolysis in the squamous subtype. PDCLs were ranked from most classi
pathway activity, and grouped into metabolic processes. PDCL ID is listed below
(B) The same signature from (A) was applied to the RNA-seq cohort of bulk tumor
on the top row. The immunogenic subtype has a transcriptional signature associ
classical (pancreatic) subtype (Bailey et al., 2016). ADEX, aberrantly differentiated
pancreatic differentiation.
(C) Heatmaps of key genes involved in glycolysis-gluconeogenesis and triglycer
classical (pancreatic) (orange) and squamous (blue) subtypes of PDCLs, with colo
which is compared with and on the whole recapitulated in bulk tumors.
(D) Relative lactate release and glucose consumption from squamous (TKCC-10 a
PDCLs were determined by colorimetric analysis. Raw values were normalized t
(E) Glycolysis activity profile of squamous and classical (pancreatic) PDCLs usin
(F) Agilent Seahorse XF Cell Mito Stress Test profiles of squamous and classical
(G) Left: ECAR values for cells treated as in (E) corrected for non-glycolytic ac
consumption resultant from processes other than mitochondrial respiration. Box
Independent experiments are shown, n = >6. ***p% 0.001, ****p% 0.0001.
(H) Left: untargeted metabolomic analysis of indicated PDCLs. Right: metaboli
classical and squamous PDCLs.
See also Figures S1 and S2 and Tables S1, S2, S3, and S4.
4 Cell Reports 31, 107625, May 12, 2020genes that govern pancreatic endodermal cell-fate determina-
tion, such as HNF1A, HNF4A, and GATA6, leading to complete
loss of endodermal identity (Bailey et al., 2016). Autosomal domi-
nant mutations in HNF4A result in hereditary forms of diabetes
mellitus referred to as maturity-onset diabetes of the young
(MODY), which is characterized by metabolic reprogramming
and early-onset, non-insulin-dependent diabetes that is closely
related to pancreatic secretory dysfunction (Stride and Hatters-
ley, 2002). Moreover, MODY patients have increased risk for
developing pancreatic cancer (Ræder et al., 2014). Given that
HNF4A and GATA6 are frequently epigenetically silenced in
squamous PDAC tumors (Bailey et al., 2016) and PDCLs (Figures
2A–2C), and mutations in these genes are associated with meta-
bolic reprogramming, we tested whether loss of these transcrip-
tion factors in a classical (pancreatic) genetic background would
drive a switch toward glycolysis (Figure 2D). We focused our
subsequent analysis on the Mayo 5289 PDCL because this cell
line clearly separated into the classical (pancreatic) subtype
following PCA analysis of RNA sequencing (RNA-seq) data (Fig-
ure S2B; Table S1) and expressed RNA and protein of each TF
(Figures 2A and 2B). Using small interfering RNA (siRNA), we tar-
getedGATA6 orHNF4A in Mayo 5289 cells and performed RNA-
seq analysis (Figures 3, S2C, and S2D; Table S5). As previously
reported, we also observed that GATA6 suppresses the expres-
sion of a squamous-like molecular phenotype (Martinelli et al.,
2017); in particular, gene set enrichment analysis (GSEA) re-
vealed that loss of GATA6 in a progenitor genetic background
led to dysregulation of gene programs involved in extracellular
matrix organization and WNT ligand biogenesis and trafficking
(Figure S2D).HNF4A knockdown was associated with increased
ECARs indicative of increased glycolysis (Figure 3B; Table S5)
and induced dysregulation of the phosphatidylinositol 3-kinase
(PI3K)-AKT signaling pathway (Figures 3C and 3D). In particular,
HNF4A knockdown was associated with a reduction in DEPTOR
and an upregulation of WNT pathway signaling molecules
WNT5A, WNT5B, WNT7B, and WNT10B (Figure 3D). When
compared with the RNA-seq analysis of bulk tumors, HNF4A
reduction recapitulated expression signatures associated withncreatic) PDCLs
showing enrichment of transcripts in pathways important in mTOR signaling
cal (pancreatic) (orange) to most squamous (blue), using gene expression or
the heatmap.
from Bailey et al. (2016). Subtype classification is depicted by annotated colors
ated with immune infiltrate and shares transcriptional networks associated the
endocrine eXocrine subtype defined by transcriptional networks important for
ide biosynthesis. Genes are ranked by most differentially expressed between
r saturation proportional to degree of either classical or squamous enrichment,
nd TKCC-26) and classical (pancreatic) (TKCC-22, Mayo 5289, andMayo 4636)
o cell counts.
g Agilent Seahorse XF Glycolysis Stress Test.
PDCLs.
idification. Right: OCR values for cells treated as in (F) corrected for oxygen
plots are annotated using one-way ANOVA. Error bars represent mean ± SD.
te pathway enrichment analysis of significantly altered metabolites between
A
HNF1A
HNF4G
FOXA2
FOXA3
PDX1
HNF1B
MNX1
HNF4A
GATA6
SOX9
ONECUT1
ONECUT3
PAX6
NKX6−1
Pa
ca
dd
11
9
TK
CC
05
Pa
n
c0
8.
13
UM
−5
9−
CL
M
ay
o
−
67
41
−1
Pa
n
c1
0.
05
UM
−0
1−
CL
TK
CC
10
TK
CC
03
UM
−9
0−
CL
UM
−6
1−
CL
TK
CC
15
UM
−5
3−
CL
UM
−1
8−
CL
TK
CC
26
TK
CC
06
TK
CC
04
TK
CC
07
Pa
ca
dd
15
9
UM
−1
22
−C
L
TK
CC
02
|TK
CC
−2
.1−
Lo
Pa
n
c0
5.
04
M
ay
o
−
64
13
−1
M
ay
o
−
49
11
−1
UM
−1
23
−C
L
TK
CC
19
TK
CC
18
M
ay
o
−
45
35
−1
TK
CC
17
UM
−1
27
−C
L
UM
−1
5−
CL
M
ay
o
−
46
36
−1
Pa
ca
dd
16
1
M
ay
o
−
46
66
−1
M
ay
o
−
48
33
−1
M
ay
o
−
40
41
−1
UM
−7
6−
CL
UM
−1
2−
CL
M
ay
o
−
42
67
−1
M
ay
o
−
60
52
−1
M
ay
o
−
61
82
−1
M
ay
o
−
52
89
−1
M
ay
o
−
61
05
−1
M
ay
o
−
58
22
−1
TK
CC
22
M
ay
o
−
61
64
−1
UM
−0
5−
CL
Pa
ca
dd
13
7
Zscore
6
4
2
0
−2
−4
Class
Pancreatic
Squamous
B
GlycolysisFatty Acid
HNF4A
GATA6
TF KD
M
ay
o
−
52
89
TK
CC
22
HNF1A
HNF4A
Pa
ca
DD
13
7
Ma
yo
52
89
Ma
yo
46
36
Actin
GATA6
C DCor=−0.5 Pval=0.0025
0
2
4
6
8
10
Lo
g 
no
rm
a
lis
ed
 c
ou
nt
s
0.2 0.4 0.6 0.8
Beta values
Cor=−0.51 Pval=0.0021
5
6
7
8
9
10
11
Lo
g 
no
rm
a
lis
ed
 c
ou
nt
s
0.0 0.2 0.4 0.6 0.8 1.0
Beta values
HNF4A GATA6
Pa
ca
D
D
13
7
Class
TK
CC
-22
TK
CC
-26
TK
CC
-06
TK
CC
-15
TK
CC
-18
TK
CC
-10
TK
CC
-2.
1
52 kDa
81 kDa
61 kDa
long
short
Figure 2. Subtype-Specific Differences in Endodermal TF Expression
(A) Heatmap showing differential expression of regulatory genes central to pancreatic endodermal cell fate determination. Note loss of pancreatic transcripts
HNF4A and GATA6 in the squamous subtype indicated by RNA-seq analysis.
(B) Immunoblots of endodermal cell fate determining transcription factors across a selection of PDCLs representative of both classical (pancreatic) and squa-
mous subtypes. 20 mg of the same protein lysate was probed with stated antibodies on different blots. Actin panel is a representative loading control (HNF1A
loading shown).
(C) Plots showing regulation of gene expression by methylation. Methylation ofHNF4A (left) orGATA6 (right) is associated with the concordant downregulation of
the indicated gene expression. Pearson correlation and adjusted p values are provided for each gene methylation comparison. Boxplot colors designate class:
squamous (blue) and classical (pancreatic) orange.
(D) Schematic representation of where the selected classical (pancreatic) PDCLs rank in terms of subtype. Expression of genes involved in endodermal cell fate
was used to rank subtype.
See also Figure S2 and Table S1.
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OPEN ACCESSthe squamous subtype, such as WNT and insulin signaling and
PI3K-AKT activation (Figure 3D), suggesting that HNF4A loss
drives metabolic reprogramming at an early stage of PDAC pro-
gression. To investigate the sufficiency of HNF4A loss to install
squamous-like metabolic reprogramming, we further knocked
down HNF4A in the classical (pancreatic) PDCLs PacaDD137,
TKCC-22, and Mayo-4636 (Figure S3A; Table S5). HNF4A
knockdown in the further subset of classical (pancreatic) PDCLs
recapitulated our previous results andwas associated with an in-
crease in glycolysis.
Loss of HNF4A Activates a Gene Expression Program
that Favors Glycolysis
Rate-limiting enzymes that mediate glucosemetabolism such as
hexokinase I and II (HK1 and HK2) were significantly induced in
HNF4A knockdown PDCLs (Figures S3B and S3C). Increased
expression of these enzymes is associated with the squamous
subtype (Figure 3G). The gene encoding ALDOB, a glycolytic
enzyme that catalyzes the conversion of fructose-1,6-bisphos-
phate to glyceraldehyde-3-phosphate, decreased following
HNF4A knockdown (Figure S3B), and a high ratio of ALDOA rela-
tive to ALDOB expression is associated with poor patient prog-nosis (Figure S3D). Furthermore, the AMP-activated protein ki-
nase (AMPK) catalytic subunit PRKAA1 was reduced following
HNF4A knockdown, with low expression also associated with
poor survival (Figures S3B and S3D).GSK3B, encoding a protein
kinase that acts as a regulator of glucose homeostasis (Reya and
Clevers, 2005) and WNT signaling (Wu and Pan, 2010), was also
significantly increased following HNF4A knockdown, with higher
protein expression also found to be associated with the squa-
mous subtype (Figures 3E–3H). In classical (pancreatic) PDCLs
with HNF4A knockdown, we consistently found increased
ECAR (Figures 3B and S3A; Table S5) and increased GSK3B
protein expression after HNF4A knockdown (Figures 3E and
3F). Collectively, these findings suggest that HNF4A loss can
mediate a switch toward a squamous subtype metabolic profile
and identify ALDOA, HK, and GSK3b as potential key molecular
regulators of glycolysis in squamous PDAC.
Targeting Glycolysis Shows Subtype Sensitivity in
Squamous PDCLs
To corroborate these findings and identify key metabolic vulner-
abilities that could be therapeutically targeted, we conducted an
siRNA-mediated gene silencing screen of metabolic targets in aCell Reports 31, 107625, May 12, 2020 5
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Figure 3. HNF4A Loss in Classical (Pancreatic) PDCLs Drives a Switch toward a Squamous-Associated Metabolic Profile
(A) Venn diagram showing the number of common and unique genes differentially expressed (p R 0.05, fold change R 2) after either HNF4A or GATA6
knockdown in the classical (pancreatic) Mayo 5289 PDCL.
(B) ECAR in classical (pancreatic) PDCLs following siRNA-mediated knockdown of HNF4A. Boxplots are annotated using one-way ANOVA, mean ± SD.
Technical replicates are shown, nR 6. For all graphs: **p% 0.01.
(C) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of significantly altered pathways identified after HNF4A knockdown in
Mayo 5289 PDCL. Adjusted p value for each annotation is represented by color scale. Gene ratio is represented by dot size. Enriched terms and pathways were
identified as significant at an adjusted p value% 0.05 and FDR% 0.05.
(D) Comparison of molecular pathways identified in bulk tumor and PDCLs RNA-seq analysis with significant gene changes following HNF4A knockdown.
(E) Right: Mayo 5289 PDCLs treated with two independent HNF4A siRNA oligos for 72 h were immunoblotted with indicated antibodies. Left: transient or stable
HNF4A knockdown in PacaDD137 and Mayo 4636 PDCLs, respectively. Actin panel is a representative loading control (HNF4A loading shown).
(F) Stable HNF4A knockdown in Mayo 5289 PDCL immunoblotted with PI3K signaling proteins identified from RNA-seq analysis. Actin panel is a representative
loading control (HNF4A loading shown).
(legend continued on next page)
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OPEN ACCESSsubset of PDCLs (Figure S4A; Table S6). Consistent with our pre-
vious findings, metabolic dependencies in squamous PDCLs
were enriched for targets falling within glycolytic metabolic
pathways (Figures S4A–S4C). Targeted inhibition of glycolysis
using either glucose analog 2-deoxy-D-glucose (2-DG) or the
pentose phosphate pathway (PPP) inhibitor 6-aminonicotina-
mide showed subtype-specific sensitivity in squamous PDCLs
(Figure S4D).
With the objective of identifying therapeutically relevant tar-
gets, we selected GSK3b for further evaluation for the following
reasons: (1) the previously established role for GSK3b in glucose
homeostasis (Embi et al., 1980; Woodgett and Cohen, 1984),
and (2) we consistently observed increased GSK3B expression
and a concomitant induction of glycolysis following HNF4A
knockdown. Furthermore, multiple phase 2 clinical trials (Clini-
calTrials.org: NCT02586935, NCT01350362, NCT02858908) us-
ing GSK3b inhibitor tideglusib highlight the potential of this com-
pound to effectively treat PDAC. As predicted, squamous PDCLs
exhibited increased sensitivity to GSK3b inhibitors, TDZD-8 and
tideglusib, in comparison with classical (pancreatic) PDCLs (Fig-
ures 4A, 4B, and S4D; Table S6), and importantly, glycolysis was
selectively reduced in squamous PDCLs (Figures 4C–4E).
A Subset of Squamous PDCLs Acquires GSK3b Drug
Tolerance after Extended Suppression of Glycolysis
Recent reports have described adaptive metabolic networks
that can compensate for metabolic targeting in PDAC (Biancur
et al., 2017). To determine whether the anti-proliferative effects
of GSK3b are sustainable after prolonged treatment, we
extended our proliferation assays to 6 days. When comparing
72- and 144-h inhibitor incubations, we observed a significant in-
crease in the half maximal inhibitory concentration (IC50) values
for TDZD-8 and tideglusib in a subset of our squamous PDCLs
(Figures 4F and 4G; Table S6), despite the sustained inhibition
of glycolysis in these cells (Figures 4H and 4I). These data sug-
gest that a subset of our squamous PDCLs can adapt to chronic
suppression of glycolysis. We next sought to identify the molec-
ular mechanism regulating metabolic adaptation in a subset of
squamous PDCLs that enabled them to tolerate GSK3b
inhibition.
GSK3b inhibition can modulate autophagy by increasing the
LKB1-AMPK-ULK signaling pathway activity and induce drug
tolerance (Sun et al., 2016). Recent studies have also shown
that suppression of glycolysis via MAPK pathway inhibition in
PDAC can lead to a greater dependency on autophagy, and
that combinations targeting bothMAPK signaling and autophagy
synergistically suppress proliferation and induce apoptosis (Bry-
ant et al., 2019; Kinsey et al., 2019). To determine whether auto-
phagy was mediating GSK3b drug tolerance in this subset of
squamous PDCLs, we tested the expression of known auto-
phagy regulators AMPK and ULK after GSK3b inhibition. Indeed,
we observed an increase in active phospho-AMPK (Thr172) and(G) A selection of PDCLs ranked from classical (pancreatic) to squamous immunob
(DEPTOR loading shown). For all blots in (E)–(G), 20 mg of the same protein lysat
(H) Correlation graph demonstrating a negative correlation of HNF4A expressio
Bailey et al. (2016) (left) and in PDCLs (right).
See also Figure S3 and Table S5.phosphor-ULK (Ser555) suggesting activation of autophagy after
GSK3bi (Figure S5). However, combinatorial targeting of AMPK
(Dite et al., 2018) and ULK (Egan et al., 2015) with SBI-
0206965 and GSK3bi (TDZD-8 or tideglusib) resulted in only a
modest rescue in inhibitor sensitivity and failed to rescue drug
tolerance (Figure S5; Table S7). Only after high concentrations
of SBI-0206965 (Figure S5) was toxicity observed, suggesting
an alternative or additional mechanism for drug tolerance/
resistance.
ATAC-Seq and Transcriptomic Analysis Reveal a
Uniquely Accessible WNT Gene Program in the Drug-
Tolerant Squamous Subtype
In an effort to identify nodes of therapy resistance, we next
sought to establish what key differences exist between groups
of squamous PDCLs that show differential adaptation to
GSK3b-mediated suppression of glycolysis. Recent studies
have established that subtypes of PDAC are associated with
distinct epigenetic landscapes (Andricovich et al., 2018; Bailey
et al., 2016; Somerville et al., 2018), and that these chromatin
states may underpin PDAC heterogeneity (Lomberk et al.,
2018). Transcriptomic analysis of a human pancreatic tumor or-
ganoid library (PTOL) established that PDAC segregates into
three subtypes with distinct methylation patterns and depen-
dency on WNT niche signaling (Seino et al., 2018). Seino et al.
(2018) showed that a subgroup of PDAC organoids designated
as W+ had the ability to harness self-produced WNT ligands.
GSK3b plays a central role in the regulation of theWNT/b-catenin
signaling pathway. When the WNT ligand is present, it binds to
specific membrane-bound receptors. This binding in turn acti-
vates an intracellular signaling cascade, which ultimately results
in b-catenin stabilization and nuclear localization. In the nucleus,
b-catenin associates with members of the TCF/LEF family of
transcription factors to regulate the transcription of various
WNT targets. GSK3b phosphorylates b-catenin triggering its
degradation and consequently reducing b-catenin nuclear accu-
mulation (Reya and Clevers, 2005; Wu and Pan, 2010).
Given the established function of GSK3b as a negative regu-
lator of WNT-mediated b-catenin signaling (Aberle et al., 1997;
He et al., 1995; Huang et al., 2017), we hypothesized that
GSK3b inhibition may mimic WNT signaling through the direct
stabilization of b-catenin, providing a survival advantage in a
subset of cells capable of harnessing self-produced WNT li-
gands. We further reasoned that different chromatin landscapes
could exist between subtypes of squamous PDCLs that would
be predictive of those expected to attain drug tolerance and
may explain the observed heterogenous response to targeted
therapy. To address these questions, we performed an integra-
tive analysis of ATAC-seq and RNA-seq data from our PDCLs.
We first established whether our PDCLs and PDAC subtypes
expressed WNT ligands. Consistent with previous reports in
PDAC organoids (Seino et al., 2018), WNT5A, WNT7A,lotted with indicated antibodies. Actin panel is a representative loading control
e was probed with stated antibodies on different blots.
n with glycolysis pathway expression from bulk tumor samples described by
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Figure 4. A Subset of Squamous PDCLs Acquires GSK3b Drug Tolerance after Chronic Suppression of Glycolysis
(A and B) Schematic of experimental setup (A) and dose-response curves (mean ± SD) (B) for classical (pancreatic) and squamous PDCLs treated with TDZD-8
(GSK3bi) or tideglusib (GSK3bi) for 72 h. Independent experiments are shown, nR 3. DMSO-treated cells were set to 100%.
(C and D) Experimental setup (C) and (top) representative Glyco Stress Test curves for (D) classical (pancreatic) or (bottom) squamous PDCLs.
(E) ECAR values (mean ± SD) after treatment with TDZD-8 or tideglusib for 4 h in classical (progenitor) and squamous PDCLs. Technical replicates are
shown, nR 5.
(F and G) Schematic of experimental setup (F) and comparison of IC50 values (mean ± SD) (G) after either 72- or 144-h treatment with either TDZD-8 (GSK3bi) or
tideglusib (GSK3bi) in PDCLs. Unpaired t test. Independent experiments are shown, n = 3.
(H and I) Schematic of experimental setup (H) and ECAR values (I) after 144-h treatment with either TDZD-8 (GSK3bi) or tideglusib (GSK3bi) in GSK3Bi-tolerant
squamous (TKCC-15, TKCC06, TKCC-18, and TKCC-26) PDCLs. Technical replicates are shown, n = 8. For all graphs: *p < 0.05; **p% 0.01; ***p% 0.001; ****p <
0.0001. Figure legend colors designate class: classical (pancreatic) = orange/brown; squamous = blue.
See also Figures S4 and S5 and Table S6.
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OPEN ACCESSWNT7B, and WNT10A mRNA were highly expressed in PDCLs,
suggesting a tumor cell-intrinsic origin for these WNT ligands
(Figure 5A; Table S1). Furthermore, high expression of WNT7A,
WNT7B, and WNT10A in clinical PDAC samples (Bailey et al.,8 Cell Reports 31, 107625, May 12, 20202016) was associated with poor survival (Figures 5B and 5C).
We next tested b-catenin protein stabilization after GSK3b inhi-
bition and as predicted found an increase in b-catenin protein
expression (Figure 5D). Importantly, treatment with the
AB
C
D
Figure 5. PDAC PDCLs Express WNT Ligands
(A) Heatmap showing mRNA expression of indicated WNT ligands in PDAC subtypes determined by RNA-seq analysis.
(B) Left: boxplots showing a significant association ofWNT7A,WNT7B, andWNT10A expression in the squamous subtype from RNA-seq analysis of bulk tumor
samples from Bailey et al. (2016). Kruskal-Wallis test. Right: boxplots showing WNT expression in the PDCLs. Wilcoxon test.
(legend continued on next page)
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OPEN ACCESSporcupine inhibitor LGK-974 was able to reduce GSK3bi (TDZD-
8 and tideglusib)-mediated b-catenin stabilization, suggesting
that secretory WNT ligands are required to mediate this tran-
scriptional effect (Figure 5D). These results demonstrate that a
subset of PDAC PDCLs can autonomously activate WNT
signaling by expressing epithelial WNT ligands, which are also
predictive of clinical outcome.
With metabolic adaptation occurring only in a subset of squa-
mous PDCLs, we next explored whether further classification
based on GSK3b inhibitor response and chromatin accessibility
could identify responsive subgroups. To this end, we ranked
our PDCLs into three response groups: GSK3b non-responders
(PacaDD137, TKCC-22, Mayo 5289, and Mayo 4636), GSK3b
initial responders (TKCC-26, TKCC-06, TKCC-15, and TKCC-
18), and GSK3b responders (TKCC-10, TKCC-2.1, and TKCC-
09) (Figure 6A). Differential peak analysis of ATAC-seq was then
performed to identify chromatin accessibility regions exhibiting
significant change among the three GSK3bi response groups
(Figures 6B and 6C). Loss of chromatin accessibility proximal to
HNF4A andGATA6 gene loci was associated with a concomitant
increase in chromatin accessibility proximal to the WNT7A and
GSK3b gene loci (Figures 6C and 6D; Table S7). Direct compari-
son of chromatin accessibility at theWNT7A locus revealed that
the subset of squamous PDCLs that demonstrated acquired
resistance to GSK3b inhibition was enriched for both intronic
and distal promoter peaks (TKCC18, TKCC-06, TKCC-15, and
TKCC-26); however, loss of these peaks was observed in the
GSK3bi-sensitive subgroup (TKCC-10, TKCC-2.1, and TKCC-
09) (Figures 6C and 6D). In line with reports that squamous
PDACsubtypes relyon super-enhancers tomediate transcription
in a highly methylated chromatin landscape (Lomberk et al.,
2018; Somerville et al., 2018),weobserved that chromatin acces-
sibility peaks in the GSK3bi-sensitive subgroup were enriched
within distal elements, suggesting a role for super-enhancers in
regulating geneexpression in this subset of cells (Figure 6E; Table
S7). GSEA using intronic and distal peaks revealed that GSK3bi-
tolerant squamous PDCLs exhibit increased chromatin accessi-
bility in subsets of genes associated with WNT, PI3K-AKT, and
Hippo signaling (Figures 6F and S6A–S6F). WNT7A was a signif-
icant hit in this analysis (FiguresS6BandS6C). Collectively, these
data suggest that GSK3bi-tolerant squamous PDCLs have ac-
cess to an amplified WNT signaling program via application of
both intronic and distal promoter usage, which may contribute
to the acquired resistance toGSK3b inhibition observed in a sub-
group of the squamous PDCLs. We next tested our GSK3bi-
tolerant (TKCC-26 and TKCC-18) and -sensitive (TKCC-10 and
TKCC-2.1) squamous PDCLs with extended GSK3bi treatment,
and as predicted by the observed enrichment of chromatin
accessibility in these cells, WNT7A expression increased in the
GSK3bi-tolerant subgroup, but not the GSK3bi-sensitive sub-
group (Figure 6G).(C) Kaplan-Meier plots showing overall survival based on data reported by Baile
(center), or WNT10A (right) expression. Blue shading represents patients with
represents patients with high WNT7A, WNT7B, or WNT10A expression, respecti
(D) Western blot for indicated targets in squamous PDCLs TKCC-26 and TKCC
(CHIR99021) was used as a positive control.
See also Figure S6.
10 Cell Reports 31, 107625, May 12, 2020To identify putative transcriptional regulators enriched in re-
gions of differential chromatin accessibility, we performed tran-
scription factor motif analysis using HOMER (Heinz et al.,
2010). Consistent with our RNA-seq analysis and reports in
low-grade (Lo-G) PDAC (Diaferia et al., 2016), the GSK3bi-resis-
tant subgroup, which is composed of classical (pancreatic)
PDCLs, was enriched for TF motifs involved in endocrine speci-
fication, such as HNF6, HNF4A, and HNF1A (Figure S7A). The
GSK3bi-sensitive subgroup was enriched for Activating
Enhancer-Binding Protein 2 Gamma (AP-2 gamma) binding mo-
tifs. AP-2 is a transcription factor that facilitates the opening of
distal enhancer regions (Pastor et al., 2018) (Figure S7A), further
supporting the notion that squamous PDCLs rely on super-en-
hancers to mediate transcription. We next established which
TF motifs were enriched in the GSK3b drug-tolerant subgroup
(Figure S7A) with the further objective of identifying potential
TFs that regulate WNT expression. Using orthogonal measures
of motif enrichment, we identified RNA and protein expression
Activating Transcription Factor-3 (ATF-3) (Figures S7A–S7D;
Table S7) as a putative regulator of WNT gene expression in
PDAC. ATF-3 has previously been established as a regulator of
WNT ligand expression (Yan et al., 2011), suggesting ATF-3 as
a potential candidate for WNT7A regulation in the GSK3bi-
tolerant subgroup. Collectively, these data demonstrate that
chromatin accessibility can be used to stratify squamous
PDAC PDCLs into two subgroups that have differential access
to TF binding motifs.
Porcupine Inhibition Overcomes WNT-Driven Acquired
Resistance to GSK3b Inhibition in Squamous PDCLs
To determine whether dysregulation of PI3K signaling is associ-
ated with increased WNT expression, we utilized a previously
described GEMM of pancreatic cancer harboring an oncogenic
Kras mutation and deletion of Pten (KCPTEN) (Kennedy et al.,
2011;Morran et al., 2014). RNAscope analysis ofWnt7a revealed
that, similar to HNF4A/GATA6 loss in squamous PDCL (Fig-
ure 7B), an increase in PI3K signaling via phosphatase and tensin
homolog (PTEN) loss was associated with higher expression of
Wnt7a, and importantly, treatment with the porcupine inhibitor
LGK-974 was able to reduce Wnt7a expression (Figures 7A
and 7B; Table S7). These results demonstrate that activation of
the PI3K pathway is associated with an increase in WNT7A
expression, which can be suppressed by porcupine inhibition.
Having established that PDAC PDCLs can harness their own
WNT-mediated b-catenin signaling, and that GSK3b inhibition
amplifies this signaling in a subset of squamous PDCLs, we
next determined whether porcupine inhibitors could effectively
suppress WNT signaling in combination with GSK3b- and
AMPK-targeted therapy. In squamous PDCLs that had previ-
ously tolerated long-term GSK3b inhibition, porcupine inhibition
sensitized cells to GSK3b andULK inhibition (Figures 7D and 7E).y et al. (2016). Tumor samples were stratified based on WNT7A (left), WNT7B
low WNT7A, WNT7B, or WNT10A expression, respectively. Yellow shading
vely. Log rank p value.
-18 after 24 h GSK3bi (tideglusib or TDZD-8) ± PORCN (LGK-974). GSK3a/b
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Figure 6. ATAC-Seq and Transcriptomic Analysis Revealed aUniquely AccessibleWNTGene Program in Squamous PDCLs that Are Tolerant
to GSK3B Inhibition
(A) Western blot (WB) for either HNF4A or GATA6 in representative PDCLs of the classical (pancreatic) or squamous subtype. 20 mg of the same protein lysate was
probed with stated antibodies on different blots. Actin panel is a representative loading control (HNF4A loading shown). (Above) Oncoplot showing somatic
mutations in genes involved in chromatin regulation. Green = structural variant (SV); purple = single-nucleotide variant (SNV) or indel.
(B) Venn diagram showing the number of common and unique annotated gene peaks in PDCLs grouped by response to GSK3bi. GSK3bi resistant = PacaDD137,
TKCC-22, Mayo 5289; GSK3bi tolerant = TKCC-26, TKCC-06, TKCC-15, TKCC-18; GSK3bi sensitive = TKCC-09, TKCC-10, TKCC-2.1.
(C) ATAC-seq density plots of accessible genes in 10 PDCLs representative of the classical (pancreatic) or squamous subtypes.
(D) ATAC-seq genomic tracks for WNT7A. Highlighted regions show subtype-specific genomic peaks. PDCLs are grouped based on response to GSK3b in-
hibitor.
(E) Chart showing the genomic distribution of ATAC-seq peaks in squamous PDCLs that are sub-grouped based on response to GSK3bi.
(F) KEGG pathway enrichment analysis of enriched pathways accessible in GSK3b-tolerant squamous PDCLs found at intronic and distal promoter sites.
(G) WNT7A expression in squamous PDCLs treated with GSK3b (TDZD-8) for 144 h. For all graphs: **p < 0.01; ***p < 0.0001.
See also Figures S6 and S7 and Table S7.
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Figure 7. Porcupine Inhibition Overcomes WNT-Driven Acquired Resistance to GSK3b Inhibition
(A) RNAscope hybridization for Wnt7a in PDAC GEMM KPC, KC Ptenfl/+, and KPC + LGK974 (porcupine inhibitor). Nuclear counterstaining is with hematoxylin.
The scale bar represents 100 mm.
(B) Quantification of samples described in (A) using HALO software.
(C) Correlation graph demonstrating a positive correlation of PI3K-AKT activation with WNT signaling in the squamous subtype from bulk tumor samples
described by Bailey et al. (2016).
(D) Schematic of experimental setup.
(E) Indicated PDCLs treated with either GSK3bi (tideglusib or TDZD-8), AMPKi/ULKi (SBI), or Porcupine-I (LGK974) alone or in combination for 144 h before cell
number analysis.
(F) GSK3b-sensitive squamous PDCLs (TKCC-10, TKCC-2.1, and TKCC-09) were treatedwithGSK3b (TDZD-8) for 144 h. Note that these cells remain sensitive to
GSK3b (TDZD-8)-targeted therapy.
**p% 0.01; ***p% 0.001. See also Table S7.
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OPEN ACCESSCombination treatment resulted in a reduction of cell prolifera-
tion and induced cytotoxicity (Figures 7D–7F; Table S7).
DISCUSSION
Prior studies have shown that PDAC is composed of two broad
transcriptomic subtypes, and that these subtypes are character-
ized by unique chromatin landscapes (Bailey et al., 2016; Collis-
son et al., 2019). We show that chromatin accessibility is an
important and largely undescribed biomarker for the delineation
of therapeutic subtypes that are otherwise indistinguishable by
transcriptomic analysis.
Due to the lack of defined genetic mutations or biomarkers in
PDAC that are predictive of therapeutic response to targeted
therapies, and the observed differential response to glycolysis12 Cell Reports 31, 107625, May 12, 2020inhibition with metabolic adaptation in a subset of squamous
PDCLs, we reasoned that stratification of PDAC using chromatin
accessibility maps and transcriptomic data represents a method
to identify patients who would respond to therapies targeting
metabolism. ATAC-seq identified amplifiedWNT signaling via in-
tronic and distal promoter usage in a subset of the squamous
PDCLs. Importantly, this analysis and other recent studies
demonstrate that the squamous subtype can be stratified into
additional subgroups that may inform response to therapy
(Chan-Seng-Yue et al., 2020). Accordingly, deeper analysis of
chromatin accessibility profiles may reveal further therapeuti-
cally relevant subgroups in PDAC. A chromatin-mediated drug-
tolerant state in cancer subpopulations has previously been
describedwhere inhibition of HDAC activity prevented the devel-
opment of drug resistance. The histone demethylase KDM5A
Article
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OPEN ACCESSwas found to be required for drug tolerance, suggesting that mu-
tations in chromatin-modifying complexes would be expected to
reduce plasticity. Indeed, the TKCC-10 and TKCC-2.1 PDCLs,
which remained sensitive to targeted therapy, have a high chro-
matin modifier mutational burden (Table S4). The chromatin
modifier KDM6A, which has been implicated in the progression
of squamous PDAC (Andricovich et al., 2018), is a common mu-
tation shared by GSK3b inhibitor-sensitive PDCLs, and in keep-
ingwith reported findings, we observe squamous-like pancreatic
cancer in these PDCLs despite the presence of GATA6.
Recent evidence also demonstrates that novel GSK-3 inhibitor
9-ING-41, which is currently being evaluated in a phase I/II trial in
patients with advanced cancer, can inhibit the growth of PDAC
cells in vitro and xenografts in vivo. Importantly, 9-ING-41 sensi-
tizes PDAC cells to gemcitabine by short-circuiting the ATR/
Chk1 DNA damage response signaling pathway, providing a
rationale for treatment regimens comprising specific GSK3 in-
hibitors in combination with standard-of-care chemotherapies
such as gemcitabine and Abraxane (Ding et al., 2019). In addi-
tion, early results from the COMPASS trial suggest that first-
line chemotherapy is associated with significantly better out-
comes in patients with tumors falling within the classical PDAC
RNA subtype (Aung et al., 2018). Based on these findings, opti-
mum strategies for GSK3B stand-alone and/or combination
therapies should include an assessment of PDAC RNA subtype
and/or PDAC chromatin accessibility.
We demonstrated that plasticity exists between subtypes, and
that siRNA-mediated loss of HNF4A and GATA6 can drive re-
programming from a classical (pancreatic) to predominantly
squamous-associated transcriptional signature. The squamous
subtype is associated with high mutational burden and a multi-
tude of chromosomal rearrangements (Bailey et al., 2016); there-
fore, reverting this subtype back to a progenitor-associated
phenotype would be expected to be more challenging than pro-
moting a switch from classical (pancreatic) to squamous. How-
ever, under certain circumstances, reprogramming from a pre-
dominantly squamous to classical (pancreatic) subtype has
been observed; for example, targeted ablation of myeloid cells
in KPC GEMMs by the selective inhibition of CSF1R produces
a profound shift in subtype (Candido et al., 2018). These data
highlight an important paracrine role for the stroma in pancreatic
cancer (PC). Likewise, stromal cues have been shown to drive
distinct changes in tumor cell metabolic pathways and to re-pro-
gram the tumor epigenome (Sherman et al., 2017). Whether a
stroma contribution to therapy-sensitive PDCLs (TKCC-10 and
TKCC-2.1) would induce drug tolerance is yet to be determined.
Establishing whether a persisting subpopulation of PDAC cells
contributes to resistance to targeted therapy or whether dy-
namic fluctuations of protein expression at the single-cell level
explain the development of therapeutic resistance remains un-
answered. Future studies will be directed at understanding
how therapy-induced tumor evolution or cell population selec-
tion evolves at the single-cell level, and how enhancer and chro-
matin reprogramming participate in mediating drug tolerance.
Identifying key regulators of these switching events could ulti-
mately prevent therapy-induced tumor evolution. Predicted tar-
gets are expected to be directed toward chromatin remodelers
and transcriptional enhancers.Apatient selection strategy based on chromatin profiling could
identify patients for GSK3b-targeted therapy. The squamous
PDCLs that remained sensitive to GSK3b inhibition have muta-
tions in LRP6 (TKCC-2.1), LKB1 (TKCC-10), and chromatin mod-
ifiers KDM6A, ARID1A, SETD2, SETBP1, and MLL3 (Table S6).
LRP6 is a receptor that transduces WNT-mediated signaling
through the canonical WNT pathway (Garg et al., 2017), and
LKB1 is a protein kinase responsible for activating AMPK
(Shackelford and Shaw, 2009). This suggests that both func-
tional WNT and AMPK signaling are required to mediate
GSK3b inhibitor tolerance; therefore, patients identified as squa-
mous, with a chromatin profile that promotes distal promoter us-
age, possibly KDM6A mutant, and harboring either LRP6 or
LKB1 mutations would be predicted to maintain sensitivity to
GSK3b-targeted monotherapy.STAR+METHODS
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Antibodies
HNF1A (D7Z2Q) Rabbit mAb Cell signaling Technology Cat# 89670S; RRID:AB_2728751
HNF4A (C11F12) Rabbit mAb Cell signaling Technology Cat# 3113; RRID:AB_2295208
GATA6 Rabbit polyclonal Abcam Cat# ab22600; RRID:AB_732529
Phospho-AMPK⍺ (Thr172) (40H9) Rabbit
mAb
Cell signaling Technology Cat# 2535; RRID:AB_331250
GSK-3b (D5C5Z) XP Rabbit mAb Cell signaling Technology Cat# 12456; RRID:AB_2636978
DEPTOR (D9F5) Rabbit mAb Cell signaling Technology Cat# 11816; RRID:AB_2750575
Hexokinase II (C64G5) mAb Cell signaling Technology Cat# 2867; RRID:AB_2232946
AMPK (D63G4) Rabbit mAb Cell signaling Technology Cat# 5832; RRID:AB_10624867
Phospho-ULK1 (Ser555) (D1H4) Rabbit
mAb
Cell signaling Technology Cat# 5869; RRID:AB_10707365
Phospho-GSK3B (Ser9) (D85E12) XP
Rabbit mAb
Cell signaling Technology Cat# 5558; RRID:AB_10013750
B-catenin (clone 14) Mouse BD Biosciences Cat# 610153; RRID:AB_397554
LKB1 (27D10) Rabbit mAb Cell signaling Technology Cat# 3050; RRID:AB_823559
ULK1 (D9D7) Rabbit mAB Cell signaling Technology Cat# 6439; RRID:AB_11178933
ATF-3 Cell signaling Technology Cat# 33593; RRID:AB_2799039
LC3B Cell signaling Technology Cat# 2775S; RRID:AB_915950
Bacterial and Virus Strains
TRC Lentiviral Human HNF4A shRNA,
Clone ID TRCN0000019189
Horizon Dharmacon Cat# RHS3979-201750396
TRC eGFP shRNA positive control Horizon Dharmacon Cat #RHS4459
psPAX2 lentiviral packaging plasmid Addgene Cat #12260
pMD2.G (VSV-G envelope expressing
plasmid)
Addgene Cat #12259
Biological Samples
TKCC PDCLs The TKCC patient derived cell lines were
provided by the Australian Pancreatic
Cancer Genome Initiative (APGI, https://
www.pancreaticcancer.net.au/) and the
Garvan Institute of Medical Research
(Sydney, Australia).
Hardie et al. (2017). DOI 10.1186/
s40170-017-0164-1
PacaDD PDCLs The PacaDD patient derived cell lines were
provided by Universita¨tsklinikum Erlangen.
R€uckert et al. (2012). https://doi.org/10.
1016/j.jss.2011.04.021
HEK293T American Type Culture Collection Cat# ATCC CRL-11268
Chemicals, Peptides, and Recombinant Proteins
6-Aminonicotinamide USBiological life sciences Cat# 258294
Dorsomorphin HCl (AMPKi) Enzo Cat# ENZ-CHM141-0005
TDZD-8 Sigma Cat# T8325
D-GLUCOSE (U-13C6, 99%) Cambridge Isotope Laboratories Cat# CLM-1396-PK
Tideglusib Stratec Cat# B1539-APE
SBI-0206965 Stratec Cat# S7885-SEL
LGK974 Selleckchem Cat# S7143
Apo-Transferrin Sigma-Aldrich Cat# T1147
D-(+)-Glucose Solution Sigma-Aldrich Cat# G8644
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DMEM/F12 GIBCO Cat# 11320-033
Dulbecco’s PBS GIBCO Cat# 14190094
EGF Recombinant Human Protein GIBCO Cat# PHG0311L
Fetal Bovine Serum (FBS) GIBCO Cat# 10270106
Ham’s F12 Nutrient Mixture GIBCO Cat# 21765-029
HEPES Buffer Solution GIBCO Cat# 15630-049
Hydrocortisone Sigma-Aldrich Cat# H0888
IMDM GIBCO Cat# 21980-065
Insulin, Human Recombinant GIBCO Cat# 12585014
L-Glutamine GIBCO Cat# 25030024
Medium M199 GIBCO Cat# 31150-022
MEM Vitamins GIBCO Cat# 11120037
MycoAlert Mycoplasma Detection Kit Lonza Cat# LT07-318
O-phosphorylethanolamine Sigma-Aldrich Cat# P0503
RPMI 1640 Medium GIBCO Cat# 21875034
3,30,5-Triiodo-L-thyronine Sigma-Aldrich Cat# T6397
0.5% Trypsin (10X) GIBCO Cat# 15400054
2-Deoxy-D-Glucose Sigma-Aldrich Cat# D8375
Oligomycin Sigma-Aldrich Cat# O4876
Crystal Violet Solution Sigma-Aldrich Cat# V5265
Lipofectamine RNAiMAX Transfection
Reagent
ThermoFisher Scientific Cat# 13778075
Lipofectamine 2000 Transfection Reagent ThermoFisher Scientific Cat# 11668027
Polybrene Transfection Reagent Millipore Cat # TR-1003-G
SYBR Select master Mix ThermoFisher Cat# 4472903
Critical Commercial Assays
CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay (MTS)
Promega Cat# G5430
Pierce BCA Protein Assay Kit Thermo Scientific Cat# 23227
Pierce ECL Western Blotting Substrate Thermo Scientific Cat# 32106
Seahorse XF Palmitate-BSA FAO Substrate Agilent Cat# 102720-100
L-Lactate Assay Kit Abcam Cat# ab56331
Glucose Uptake Assay Kit Abcam Cat# ab136955
Seahorse XF glycolysis stress test kit Aglient Cat# 103030-100
Seahorse XFe96 FluxPaks Agilent Cat# 102416-100
RNeasy Mini Kit QIAGEN Cat# 74104
Illumina Tagment DNA TDE1 Enzyme and
Buffer kit
Illumina Cat# 20034197
MinElute PCR Purification Kit QIAGEN Cat# 28004
NEBNext High-Fidelity 2X PCR Master Mix New England Biolabs Cat# M0541S
Agencourt AMPure XP beads fisher scientific Cat# 10136224
Bioanalyzer DNA analysis Agilent Cat# 5067
AffinityScript Multiple temperature cDNA
synthesis kit
Agilent Technologies Cat# 200436
Deposited Data
Human Pancreatic Cancer DNA and RNA-
seq data
Bailey et al. (2016). https://doi.org/10.1038/
nature16965
European Genome-phenome Archive
(EGA): accession code EGAS00001000154
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Human Pacreatic Cancer gene expression
and genotyping data
Bailey et al. (2016). https://doi.org/10.1038/
nature16965
NCBI Gene Expression Omnibus (GEO)
under accession codes GSE49149 and
GSE36924
Human Pancreatic Cancer PDCLATAC-seq
sequencing data
This paper BioProject: PRJNA630992
Tables S1, S2, S3, S4, S5, S6, and S7 This paper https://dx.doi.org/10.17632/74s7crj7xj.1
Experimental Models: Organisms/Strains
Pdx1-Cre, LSL-KrasG12D Hingorani et al. (2005) DOI:10.1016/j.ccr.2005.04.023
Ptenfl and LSL-Trp53
R172H Kennedy et al. (2011) DOI:10.1016/j.molcel.2011.02.020
Oligonucleotides
ON-TARGETplus Non-targeting Pool/
siRNA #1
Dharmacon Cat# D-001810
ON-TARGETplus HNF4A SMARTpool
siRNA
Dharmacon Cat# L-003406-00
Hs_GAPDH_1_SG QuantiTect Primer QIAGEN Cat# QT00079247
Hs_WNT7A_1_SG QuantiTect Primer QIAGEN Cat# QT00012278
Hs_LGR5_1_SG QuantiTect Primer Assay QIAGEN Cat# QT00027720
Hs_AXIN2_1_SG QuantiTect Primer Assay QIAGEN Cat# QT00037639
ON-TARGETplus Human HNF4A (3172)
siRNA - Individual
horizon Cat# J-003406-08-0002
ON-TARGETplus Human HNF4A (3172)
siRNA - Individual
horizon Cat# J-003406-09-0002
ON-TARGETplus Human GATA6
SMARTpool siRNA
Dharmacon Cat# L-008351-00-0005
Software and Algorithms
Dnet Hai Fang and Julian Gough https://cran.r-project.org/web/packages/
dnet/index.html
ClueGo Cytoscape Bindea et al., 2009 http://apps.cytoscape.org/apps/cluego
CluePedia Cytoscape Bindea et al., 2013 http://apps.cytoscape.org/apps/cluepedia
RedeR Castro et al., 2012 https://bioconductor.org/packages/
release/bioc/html/RedeR.html
MACS2 Zhang et al., 2008 https://taoliu.github.io/MACS/
Cytoscape Shannon et al., 2003 https://cytoscape.org/
ComplexHeatmap Gu et al., 2016 https://bioconductor.org/packages/
release/bioc/html/ComplexHeatmap.html
Ggpubr CRAN https://cran.r-project.org/web/packages/
ggpubr/index.html
Seaborn python https://seaborn.pydata.org/
Ggfortify Tang et al., 2016 https://cran.r-project.org/web/packages/
ggfortify/index.html
ggplot2 Wickham, 2009 https://cran.r-project.org/web/packages/
ggplot2/index.html
qSV omicX https://omictools.com/qsv-tool
qSNP omicX https://omictools.com/qsnp-tool
GATK Broad Institute https://gatk.broadinstitute.org/hc/en-us
Pindel Sanger https://github.com/genome/pindel
HOMER Heinz et al., 2010 http://homer.ucsd.edu/homer/
STRING Szklarczyk et al., 2015 https://string-db.org/cgi/input.pl
ChipSeeker Yu et al., 2015 https://bioconductor.org/packages/
release/bioc/html/ChIPseeker.html
RSEM Li and Dewey, 2011 https://deweylab.github.io/RSEM/
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STAR Dobin et al., 2013 https://code.google.com/archive/p/
rna-star/
ChAMP Morris et al., 2014 https://bioconductor.org/packages/
release/bioc/html/ChAMP.html
Gviz Hahne and Ivanek, 2016 https://bioconductor.org/packages/
release/bioc/html/Gviz.html
DiffBind Ross-Innes et al., 2012 https://bioconductor.org/packages/
release/bioc/html/DiffBind.html
Clipper Martini et al., 2020 https://bioconductor.org/packages/
release/bioc/html/clipper.html
Genefu//// Gendoo et al., 2020 https://www.bioconductor.org/packages/
release/bioc/html/genefu.html
GSVA Ha¨nzelmann et al., 2013 https://bioconductor.org/packages/
release/bioc/html/GSVA.html
ConsensusClusterPlus Wilkerson and Hayes, 2010 http://bioconductor.org/packages/release/
bioc/html/ConsensusClusterPlus.html
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OPEN ACCESSLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagent should be directed to and will be fulfilled by the Lead Contact, Dr Peter
Bailey. Distribution of Mayo and PacaDD PDCLs are restricted by Material Transfer Agreements (MTAs). TKCC PDCLs are available
upon request from the Australian Pancreatic Cancer Genome Initiative (APGI) at https://www.pancreaticcancer.net.au/
bioresource-pdcls/.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
APGI: Sydney South West Area Health Service Human Research Ethics Committee, western zone (protocol number 2006/54); Syd-
ney Local Health District Human Research Ethics Committee (X11- 0220); Northern Sydney Central Coast Health Harbour Human
Research Ethics Committee (0612- 251M); Royal Adelaide Hospital Human Research Ethics Committee (091107a); Metro South Hu-
man Research Ethics Committee (09/ QPAH/220); South Metropolitan Area Health Service Human Research Ethics Committee (09/
324); Southern Adelaide Health Service/Flinders University Human Research Ethics Committee (167/10); Sydney West Area Health
Service Human Research Ethics Committee (Westmead campus) (HREC2002/3/4.19); The University of Queensland Medical
Research Ethics Committee (2009000745); Greenslopes Private Hospital Ethics Committee (09/34); North Shore Private Hospital
Ethics Committee. Johns Hopkins Medical Institutions: Johns Hopkins Medicine Institutional Review Board (NA00026689). Ethik-
kommission an der Technischen Universita¨t Dresden (Approval numbers EK30412207 and EK357112012). University of Michigan
Institutional Review Board (HUM00025339). Mayo Clinic Institutional Review Board (# 66-06)
Cell Lines
Patient derived cell lines (PDCLs) were generated as previously described (Chou et al., 2018; Pal et al., 2014; R€uckert et al., 2012;
Waddell et al., 2015). PDCLs were cultured in conditions specifically formulated for each individual line based on growth prefer-
ences and those resulting in cell lines that most closely resembled physiological cells from the initial tumor. Detailed culture media
formulations for TKCC PDCLs are previously described in Hardie et al. (2017). Mayo PDCLs were cultured in DMEM/F12 (Life tech-
nologies, #11320-074) supplemented with 10% FBS (ThermoFisher Scientific, #SH30084.03) and 15mM HEPES (Life technologies,
#15630-049). PacaDD lines were grown in DMEM (Life technologies, #41965-039), 10% FBS and KSFM formulation (Life technol-
ogies, #17005-059, Life technologies, #37000-015). Cells were grown in a humidified environment with either 5% or 2% O2. All cell
lines were profiled by short tandem repeat (STR) DNA profiling as unique (CellBankaustralia.com). Cell lines were tested routinely
for mycoplasma contamination using MycoAlert PLUS Mycoplasma Detection Kit (Lonza, #LT07 – 318). Information on the sex of
the PDCLs is not available. HEK293T cells were obtained from the American Type Culture Collection (ATCC CRL-11268) and main-
tained in DMEM (Life Technologies, #11960044) supplemented with 10% FBS and 2mM L-glutamine (Life Technologies,
#25030081).Cell Reports 31, 107625, May 12, 2020 e4
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Pdx1-Cre, LSL-KrasG12D, Ptenfl, and LSL-Trp53R172H mice have been described previously (Hingorani et al., 2005; Kennedy et al.,
2011). Mice on a mixed strain background were kept in conventional animal facilities and experiments carried out in compliance with
UK Home Office guidelines and approved by the University of Glasgow Animal Welfare and Ethical Review Board. Mice were gen-
otyped by Transnetyx (Cordova, Tennessee, USA). Adult mice of both sexes were used in studies. Mice were treated with 5mg/kg
LGK974 in 0.5% methylcellulose / 0.5% Tween 80, p.o. BID. Animals were sacrificed as per institutional guidelines, and tissues
removed and fixed in 10% buffered formalin.
METHOD DETAILS
Western blotting
Protein lysates were harvested in RIPA lysis buffer supplemented with PhosSTOP easypack (Roche, #04906845001) and cOmplete
Protease Inhibitor Cocktail (Roche, #4693116001) and quantified using Pierce BCA protein assay kit (ThermoFisher, #23225).
Following SDS-PAGE, proteins were transferred to Nitrocellulose membranes (Amersham Biosciences, #45-001-227). To block,
membranes were incubated in Tris-buffered saline (TBS) containing 5% BSA (Sigma, #A7906) and 0.1% Tween 20 (TBS-T) for 1hr
before incubation with the primary antibody overnight at 4. Membranes were then washed with TBS-T followed by incubation
with secondary antibodies (Anti-Mouse IgG, Jackson ImmunoResearch #715-035-150, anti-Rabbit IgG Jackson ImmunoResearch
#111-035-144) for 1hr at room temperature. Membranes were visualized using Pierce ECL western blotting substrate (ThermoFisher
Scientific, Cat #32106) on BioRad chemiDocMP Imaging system. Antibodies used are listed in STARMethods Key Resources Table.
Nucleic acid extraction
DNA and RNA extractions were performed using QIAGEN DNeasy Blood & Tissue kit (Cat #69504) or QIAGEN RNeasy Mini kit (Cat
#74104) respectively, according to manufacturer’s specifications.
Quantitative RT-PCR
cDNA was synthesized according to AffinityScript Multiple temperature cDNA synthesis kit instructional manual (Agilent Technolo-
gies, Cat #200436). Quantitative reverse transcription (RT)-PCR analyses were performed using SYBR Select Master Mix (Thermo-
Fisher, Cat #4472903) according to reference manual and signals were acquired using QuantStudio 3 (ThermoFisher Scientific).
GAPDH mRNA levels were used for data normalization. Each experiment was performed in triplicate. The primers used for quanti-
tative RT-PCR are listed in the Key Resources Table.
Whole-genome library preparation
Whole-genome libraries were generated using either the Illumina TruSeq DNA LT sample preparation kit (Illumina, Part no. FC-121–
2001 and FC-121–2001) or the Illumina TruSeq DNA PCR-free LT sample preparation kit (Illumina, Part no. FC-121–3001 and FC-
121–3002) accord- ing to the manufacturer’s protocols with some modifications (Illumina, Part no. 15026486 Rev. C July 2012
and 15036187 Rev. A January 2013 for the two different kits respectively). For the TruSeq DNA LT sample preparation kit, 1 mg of
gDNA was used as input for fragmentation to 300 bp, followed by a SPRI-bead clean up using the AxyPrep Mag PCR Clean-Up
kit (Corning, Part no. MAG-PCR-CL-250). After end-repair, 3ʹ adenylation and adaptor ligation, the libraries were size- selected using
a double SPRI-bead method to obtain libraries with an insert size 300 bp. The size-selected libraries were subjected to 8 cycles of
PCR to produce the final whole-genome libraries ready for sequencing. For the TruSeq DNA PCR- free LT sample preparation kit,
1 mg of gDNA was used as input for fragmentation to 350 bp, followed by an end-repair step and then a size-selection using the
double SPRI-bead method to obtain libraries with an insert size 350 bp. The size- selected libraries then underwent 3ʹ adenylation
and adaptor ligation to produce final whole genome libraries ready for sequencing. Prior to sequencing, whole- genome libraries were
qualified via the Agilent BioAnalyzer 2100with the High Sensitivity DNA Kit (Agilent, Part no. 5067–4626). Quantification of libraries for
clustering was performed using the KAPA Library Quantification Kit - Illumina/ Universal (KAPA Biosystems, Part no. KK4824) in com-
bination with the Life Technologies Viia 7 real time PCR instrument.
RNA sequencing library generation and sequencing
RNA-seq libraries were generated as described in TruSeq Stranded Total RNA Sample Preparation Guide (illumina, part no.
15031048 Rev. E October 2013) using Illumina TruSeq Stranded Total RNA LT sample preparation kit. Ribosomal depletion step
was performed on 500 ng of total RNA using Ribo- Zero Gold (Illumina, 20020598 and 20020492) followed by a 8 min heat fragmen-
tation step aimed at producing libraries with an insert size between 120bp-200bp. First strand cDNA was synthesized from the en-
riched and fragmented RNA using SuperScript II Reverse Transcriptase (Thermofisher, 18064014) and random primers. Second
strand synthesis was performed in the presence of dUTP. Following 30 adenylation and ligation of adaptors to the dsDNA, libraries
were subjected to 13 cycles of PCR. RNA-seq libraries were quantified using PicoGreen assay (Thermofisher, P11496) and sized and
qualified using an Agilent 4200 TapeStation with Agilent D1000/High sensitivity ScreenTape (Agilent, 5067-5584). Libraries were
normalized to 4nM and pooled before clustering using a cBot2 followed by 75bp paired-end sequencing on a HiSeq 4000 sequencer
(illumina). PDCL normalized RNA expression data is provided in Table S1.e5 Cell Reports 31, 107625, May 12, 2020
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All libraries were sequenced using the Illumina HiSeq 2000/2500 systemwith TruSeq SBS Kit v3 - HS (200-cycles) reagents (Illumina,
Part no. FC-401-3001), to generate paired-end 101 bp reads.
Copy number analysis
Matched tumor and normal patient DNA was assayed using Illumina SNP BeadChips as per manufacturer’s instructions (Illumina,
San Diego CA) (HumanOmni1-Quad or HumanOmni2.5–8 BeadChips) and analyzed as previously described. PDCL copy number
variance is provided in Table S4.
Identification and verification of structural variants
The Somatic structural variant pipeline was identified using the qSV tool. A detailed description of its use has been recently published
(Nones et al., 2014; Waddell et al., 2015). PDCL mutations are provided in Table S4.
Identification of and verification of point mutations
Substitutions and indels were called using a consensus calling approach that included qSNP, GATK and Pindel. The details of call
integration and filtering, and verification using orthogonal sequencing and matched sample approaches are as previously described
(Nones et al., 2014; Waddell et al., 2015).
Mutational signatures
Mutational signatures were defined for genome-wide somatic substitutions, as previously described (Waddell et al., 2015).
Metabolite measurements
Steady state metabolomics experiments were performed in cell lines grown to 80% confluence on 6cm dishes in biological tripli-
cate. Polar and nonpolar metabolites were extracted using Chloroform:Methanol:Water (1:3:1) extraction at 4. Samples were placed
on a rocker for 1hr at 4 then vortex at 4 for 5 minutes, followed by centrifugation at 13,000 g for 3 minutes at 4. Supernatant was
stored at 80 until ready for analysis. Metabolite levels were analyzed by Hydrophilic interaction liquid chromatography (HILIC) on
the Dionex UltiMate 3000 RSLC system (ThermoFisher Scientific, Hemel Hemstead, UK) using a ZIC-pHILIC column (150mm x
4.6mm x 5 mM) (Merck). The column was maintained at 30 and samples were eluted with a linear gradient (20mM ammonium car-
bonate in water, and acetonitrile) over 26 mins at a flow rate of 300uL/min. Instrument .raw files were converted to positive and nega-
tive ionisation mode mzXML files. These files were then analyzed using the XCMS/MZMatch/IDEOM pipeline (Creek et al., 2012).
PDCL metabolomic measurements are provided in Table S2.
Extracellular Metabolic Flux Assays
Measurements of extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were obtained utilizing the Seahorse
XFe96 Analyzer (Seahorse Biosciences) as previously described (Pike Winer and Wu, 2014). In brief, cells were seeded in their
respective, fully supplemented medium at a range of densities optimized for each PDCL. 45 minutes prior to starting the assay, cells
were equilibrated in seahorse XF DMEM media (Agilent, cat# 103575-100) supplemented with 2mM L-glutamine at 37C in a non-
CO2 incubator. During the assay, indicated compounds were injected into wells at 18-minute intervals. All results were normalized
to total cellular protein content per well by RIPA extraction followed quantification with BCA protein assay kit (ThermoFisher Scien-
tific, #23227,) in a 96-well format, with absorbance measured using a Tecan Infinite 200 plate-reader.
Glycolysis Stress Test
This assay was initiated in the absence of glucose, with 10 mM glucose, 2.5 mMof Oligomycin (O4876, Sigma-Aldrich) and 50 mM 2-
DG (Sigma-Aldrich, #D8375) sequentially added to generate a profile of glycolysis under various conditions, as described previously
(Pike Winer and Wu, 2014). PDCL ECAR values after the glycolysis stress test are provided in Table S3. PDCL ECAR values after
GSK3bi are provided in Table S6.
FAO Assay
This assay functions as an extension to the Mitochondrial Stress Test described by Seahorse Biosciences. In order to stimulate con-
sumption of endogenous fatty acid (FA) reserves, 24-hours prior to beginning this assay, cells were cultured in substrate limited me-
dia: DMEM (cat# A1443001) supplemented with 0.5mM glucose, 0.5mM L-carnitine (Sigma-Aldrich, #C0283) and 1% FBS. FAOwas
quantified as ameasurement of OCR upon treatment of cells with either 40 mMFAO inhibitor Etomoxir (Sigma-Aldrich, #E1905) or the
FA-palmitate, purchased as Seahorse XF Palmitate-BSA FAO Substrate (Seahorse Biosciences, #102720- 100), as described pre-
viously (PikeWiner andWu, 2014). Initial OCR readings of the assay represent basal levels of respiration in the PDCLs, with sequential
additions of 2.5 mMOligomycin, 1.6 mMCCP (Sigma-Aldrich, #C2759) and a 1 mMcombination of Antimycin (Sigma-Aldrich, #A8674)
and Rotenone (Sigma-Aldrich, #R8875) providing a profile of OCR under different metabolic conditions. PDCL OCR values after the
FAO assay are provided in Table S3.Cell Reports 31, 107625, May 12, 2020 e6
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The L-Lactate content of culture media wasmeasured using the colorimetric-based L-Lactate Assay Kit (Abcam, #ab56331) accord-
ing to manufacturer’s specifications. 3 3 104 cells were plated in their respective, fully supplemented medium and 24 hours after
seeding, this medium was replaced. Cells were cultured for a further 48 hours before medium was taken for analysis. Each test
was performed in duplicate, with output adjusted to background lactate levels in medium and normalized to total cell count. Glucose
consumption was quantified via the colorimetric-based Glucose Uptake Assay Kit (Abcam, #ab136955) as per the manufacturer’s
protocol. Each test was performed in triplicate and normalized to cellular protein content. PDCL lactate production and glucose con-
sumption values are provided in Table S3.
In Vitro Cytotoxicity assays
Cells were plated in 96-well plates and treated with serial dilutions of indicated inhibitors 24hrs after plating for indicated time points.
Cell viability was determined using CellTiter 96 Aqueous non-radioactive cell proliferation assay composed of solutions of a tetra-
zolium compound [3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and
an electron-coupling reagent (phenazine methosulfate; PMS) (Promega, Madison, WI, USA). The assay was performed at an absor-
bance of 490 nm using an ELISA plate reader (Tecan Trading AG). Background absorbance was corrected for by wells containing
medium alone and the absorbance was normalized to 100% (DMSO). 10 technical replicates were performed for 3 independent ex-
periments. IC50 calculation and dose response curves were generated using GraphPad Prism 8 (GraphPad Software Inc, La Jolla
CA). Normalized cell viability values are provided in Table S6 (GSK3bi single agent) and Table S7 (GSK3bi + ULKi + PORCNi triple
treatment).
In situ hybridization
In situ hybridization staining was performed on 4um formalin fixed paraffin embedded sections which had previously been ovened at
600C for 2 hours. In situ hybridization detection for WNT7a (401128) and PPIB (313918) (Advanced Cell Diagnostics, Hayward, CA)
mRNA was performed using RNAscope 2.5 LS (brown) detection kit (322100; Advanced Cell Diagnostics, Hayward, CA) and per-
formed on a Leica Bond Rx autostainer strictly adhering to the manufacturer’s instructions. WNT7A RNAscope analysis is provided
in Table S7.
ATACseq library preparation
ATAC-seq libraries were prepared similarly to previously describedmethods in Buenrostro et al. (2015). A suspension of 100,000 cells
were harvested from representative PDCLs and centrifuged for 5 mins at 600 g at 4C. The cell pellet was washed in 50uL PBS, then
centrifuged for 5 mins at 600 g, 4C. Supernatant was removed and 50uL ATAC-seq cold lysis buffer (10mM Tris-HCl pH 7.4, 10mM
NaCl, 3mM MgCl2, 0.1% IGEPAL-630) was added to the pellet and gently dislodged. The pellet was immediately centrifuged for
10 mins at 600 g 4C. The transposition mixture was then made by combining 25uL TD (2X reaction buffer from Nextera kit
(Cat#20034197)), 4.7uL TDE1 (Nextera Tn5 Transposase from Nextera kit (Cat#20034197)) and 22.5uL nuclease-free H20. The pellet
was then resuspended in the transposition reaction mix and incubated 37C for 30 mins. Immediately following transposition, the
DNA was purified using the QIAGEN MinElute PCR purification kit (Cat# 28004). Eluted transposed DNA was resuspended in
10uL buffer EB. To amplify transposed DNA fragments the following was combined in a 0.2mL PCR tube: 10uL transposed DNA,
10uL nuclease-free H20, 2.5 uL 25uMPCRPrimer 1, 2.5 uL 25uMBarcoded PCR primer 2, 25uL NEBNext High-Fidelity 2X PCRmas-
ter mix (Cat# m0541S). Thermal cycles used were as follows: 1 cycle: 5mins at 2C, 30 s at 98C, 5 cycles: 10 s at 98C, 30 s at 63C,
1min at 72C. To calculate the additional number of cycles required for library amplification a qPCRwas performed by combining the
following: 5uL of previously PCR-amplified DNA, 4.2 uL H20, 0.4 uL 25uM primer 1, 0.4 uL 25uM primer 2, 5uL 2X SYBR green, 5uL
NEB PCRmaster mix. qPCR thermal cycles used were as following: 1 cycle: 30 s at 98C, 20 cycles: 10 s at 98C, 30 s at 63C, 1 min
at 72C. To calculate additional number of cycles required, plot linear Rn versus cycle and determine the cycle number that corre-
sponds to one-third of the maximum florescent intensity. The remaining 45uL PCR reaction was run the additional cycle number
determined by qPCR. Cycle as follows: 1 cycle: 30 s at 98C, N cycles: 10 s at 98C, 30 s at 63C, 1 min at 72C. Amplified library
was purified using QIAGEN Minelute PCR purification kit (Cat# 28004). Library was eluted in 20uL EB buffer. Excess adapters were
removed using AMPure XPmagnetic beads (Cat# 10136224) and DynaMag-2 magnetic rack. Preliminary library analysis for concen-
tration and size distribution was performed using Agilent High sensitivity DNA kit (Cat# 5067) on the Agilent Bioanalyzer.
siRNA screening
Prior to siRNA screening, optimal cell number per well and optimal reverse transfection reagents for each PDCL were identified by
assessing transfection efficiency, using six different transfection reagents (Dharmafect 1-4, RNAimax, Lipofectamine 2000), using the
manufacturers’ instructions. Experimental conditions were selected that met the following criteria: (i) compared to amock control (no
lipid, no siRNA), the transfection of non-silencing negative control siRNA caused no more than 20% cell inhibition; (ii) compared to
non-silencing negative control siRNA, the transfection of PLK1– targeting siRNA caused more than 80% cell inhibition; (iii) cell con-
fluency reached 70%within the range of 4-7 days (Campbell et al., 2016). The later criteria allowed assays to be terminatedwhile cells
were in growth phase. Once optimal conditions were established, each PDCLwas reverse transfected in a 384 well-plate format with
a custom siGENOME siRNA library (Dharmacon, USA) designed to target 714 kinase coding genes, 256 protein phosphatase codinge7 Cell Reports 31, 107625, May 12, 2020
Article
ll
OPEN ACCESSgenes, 722 genes implicated in energymetabolism, 73 tumor suppressor genes and 166 genes involved in the repair of DNA damage.
Each well in the 384 well-plate arrayed library contained a SMARTpool of four distinct siRNA species targeting different sequences of
the target transcript. Each plate was supplemented with non-targeting siCONTROL and siPLK1 siRNAs (Dharmacon, USA). Cell
viability was estimated five days after transfection using a luminescent assay detecting cellular ATP levels (CellTiter-Glo, Promega).
Luminescence values were processed using the cellHTS2 R package (Boutros et al., 2006). To evaluate the effect of each siRNA pool
on cell viability, we log2 transformed the luminescence measurements and then centered these to the median value for each plate.
The plate-centered data were scaled to the median absolute deviation (MAD) of the library as a whole to produce robust Z-scores. All
screens were performed in triplicate. Screens judged to have poor dynamic range (Z’ factor < 0) (Zhang et al., 1999) or poorly corre-
lated replicates (r < 0.7) were excluded during an evaluation of screen quality. Z scores were adjusted using a quantile normalization
(Parrish and Spencer, 2004).
Lentiviral transfection
To generate lentiviral particles, 2x106 HEK293FT cells were transfected with a mixture of 2 mg shRNA (see Key Resources Table for
shRNA contructs), 0.5 mg pMD2.G (Addgene, Cat#12259) and 1 mg psPAX2 (Addgene, Cat #12260) plasmid DNA using Lipofect-
amine 2000 (ThermoFisher Scientific, Cat #11668027) as per manufacturers guidelines. Forty-eight hours post transfection, media
was removed and filtered through a 0.45 mm Millex-AC filter (Millipore, Cat #SLHV004SL) and mixed at a 1:1 ratio with normal
PDCL growth medium, supplemented with polybrene (Millipore, Cat #TR-1003-G) to a final concentration of 5 mg/ml, and added
to PDCLs for twenty-four hours. PDCLs were subjected to two rounds of lentiviral infection prior to selection in 2 mg/ml of puromycin
(GIBCO, Cat #A1113802).
HNF4A and GATA6 siRNA knockdown
For siRNA mediated knockdown experiments, siRNA constructs were purchased from Dharmacon (Key Resources Table) and
PDCLs were transfected with 25 pmol siRNA using Lipofectamine RNAiMAX transfection reagent (ThermoFisher Scientific, Cat
#13778075) according to manufactures instructions for 6-well format. 72hrs following transfection, PDCLs were analyzed for target
knockdown (qRT-PCR andWestern Blot analysis) and subjected to RNA-seq or Glycolysis Stress Test analysis. PDCL siHNF4A and
siGATA6 RNA-seq, and siHNF4A ECAR values are provided in Table S5.
QUANTIFICATION AND STATISTICAL ANALYSIS
siRNA screen analysis
siRNA ‘‘hits’’ were identified by calculating the median absolute deviation of normalized Z-scores for a given siRNA across all sam-
ples and identifying sample Z scores greater than or equal to 2 x the median absolute deviation. This analysis generated a ‘‘seed’’
matrix (n siRNA hits xm samples) whichwas used as starting input for the RandonWalk with Restart (RWR) algorithm as implemented
by the R package dnet (Fang and Gough, 2014). This algorithm was used to identify functionally important subnetworks associated
with cell viability from a curated protein-protein interaction network STRING v 10 (Szklarczyk et al., 2015). Considering the complex
nature of topological features of human interactome data, we introduce a randomization-based test to evaluate the candidate inter-
actors utilizing 1000 topologically matched random networks. Candidate interactors that remain significant (i.e., p edge < 0.05) were
identified and a consensus subnetwork was constructed by collapsing all sample-specific results. The resulting network was visu-
alized using RedeR (Castro et al., 2012). PDCL siRNA screen analysis is provide in Table S6.
RNaseq analysis
RNA-seq read mapping was performed by either the bcbio-nextgen RNaseq pipeline (https://bcbio-nextgen.readthedocs.io/en/
latest/) or RSEM package (Li and Dewey, 2011). Briefly, after quality control and adaptor trimming, reads were aligned to the
GRCh37 genome build using either STAR (Dobin et al., 2013) or RSEM. Count data, obtained from the respective RNaseq pipelines,
was normalized using the R/Bioconductor package ‘‘DESeq2’’ to produce rlog transformed expression values. The Combat function
from the R package sva was subsequently used to correct for batch effect and to produce an integrated matrix of normalize expres-
sion values. This matrix was used for all downstream analyses.
WGCNA analysis
Weighted gene co-expression network analysis (WGCNA) was used to generate a transcriptional network from rlog normalized RNa-
seq data (Langfelder and Horvath, 2008). Briefly, WGCNA clusters genes into network modules using a topological overlap measure
(TOM). The TOM is a highly robust measure of network interconnectedness and essentially provides a measure of the connection
strength between two adjacent genes and all other genes in a network. Genes are clustered using 1- TOM as the distance measure
and gene modules are defined as branches of the resulting cluster tree using a dynamic branch-cutting algorithm.
Themodule eigengene is used as ameasure ofmodule expression in a given sample and is defined as the first principle component
of amodule. To relate sample traits of interest to genemodules, sample traits were correlated tomodule eigengenes and significance
determined by a Student asymptotic P value for the given correlations. To relate gene modules to PDCL subtypes, module eigen-
genes were stratified by subtype and subtype significance determined by Kruskal–Wallis test.Cell Reports 31, 107625, May 12, 2020 e8
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bulk). Two composite measures were used to assess module preservation namely, median rank and Zsummary. Median rank was
used to identify module preservation and Zsummary to assess significance of module preservation via permutation testing. Permu-
tation was performed 200 times, modules with a Zsummary score > 10 indicate preservation, 2 to 10 indicate weak tomoderate pres-
ervation and < 2 indicate no preservation in the permutations.
Identification of significant subtype specific changes in pathways and/or processes
The R package clipper (Martini et al., 2013) was used to identify pathways and/or processes showing significant change between
PDCL subtypes. clipper implements a two-step empirical approach, employing a statistical analysis of means and concentration
matrices of graphs derived from pathway topologies, to identify signal paths having the greatest association with a specific
phenotype.
Methylation analysis
Methylation analysis was performed using Illumina 450K arrays as previously described in (Bailey et al., 2016). Probe filtering, normal-
ization, and differential methylation analysis was performed using the package ‘ChAMP’ (Morris et al., 2014) using default settings.
Plots showing regions of differentially methylation were generated using the GVIZ package (Hahne and Ivanek, 2016).
ATACseq analysis
Sequencing reads were trimmed and aligned to assembly GRCh38 using bwa mem. Duplicate reads and reads mapping to mito-
chondrial sequences were subsequently removed. Chromatin accessibility peaks were called using MACS2 (Zhang et al., 2008)
and annotated using HOMER (Heinz et al., 2010) and/or ChipSeeker (Yu et al., 2015). Differential accessibility analysis was performed
using the R/Bioconductor package DiffBind (Ross-Innes et al., 2012). PDCL ATAC-seq analysis is provided in Table S7.
Generation of subtype specific signatures
Pathways and/or processes identified by clipper analysis were selected for signature generation. Subtype specific gene signatures
representing each pathway and/or process were generated by selecting significant genes in a given graph. Gene weights in each
signature represent estimated Z-scores generated from Student t test p values with direction of change provided by the t test
statistic. The ‘sig.score’ function from the R package genefu (Haibe-Kains et al., 2012) was used to calculate a specific signature
score in a given sample using the signatures generated for each pathway and/or process. PDCL bulk signature scores are provided
in Table S1.
Gene set enrichment of PDAC subtypes
Gene set enrichment was performed using the R package ‘GSVA’ (Ha¨nzelmann et al., 2013). Gene sets representing PDAC subtypes
were generated as previously described (Bailey et al., 2016).
Clustering and subtype assignment
The package ‘ConsensusClusterPlus’ (Wilkerson and Hayes, 2010) was used to classify PDCLs according to the expression signa-
tures defined in Moffitt et al. (2015) and Bailey et al. (2016). Gene sets representing PDAC subtypes were generated as previously
described. PDCL consensus clustering using Bailey classification (Squamous versus Classical) differential gene expression analysis
is provided in Table S1.
Pathway analysis
Ontology and pathway enrichment analysis was performed using the R package ‘dnet’ and/or the ClueGO/CluePedia Cytoscape
(Bindea et al., 2013; Bindea et al., 2009) plugins as indicated. Visualization and/or generation of network diagrammes was performed
using either Cytoscape (Shannon et al., 2003) or the R package RedeR (Castro et al., 2012).
Plot generation
Heatmaps and oncoplots were generated using the R package ComplexHeatmap (Gu et al., 2016). Dotcharts, density plots and box-
plots were generated using the R package ggpubr. Violin plots were generated using the python package Seaborn.Biplot was gener-
ated using the R package ggfortify (Tang et al., 2016). All other plots were generated using the R package ggplot2 (Wickham, 2009).
Statistical analysis
Statistical parameters are reported in the figures and figure legends. Data are considered significant if p < 0.05. Data are presented as
mean ± SD for technical replicates, or mean ± SEM for biological replicates. Data was analyzed using unpaired Student t test when
comparing two conditions. One-way ANOVA with Tukey’s multiple comparisons test was performed on comparisons of more than
two conditions. Two-way ANOVAwas performed on PDCL survival triple inhibitor studies. Kruskal–Wallis test was applied to the indi-
cated stratified scores to determine whether distributions were significantly different. Fisher’s exact tests were used to evaluate thee9 Cell Reports 31, 107625, May 12, 2020
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OPEN ACCESSassociation between dichotomous variables. Survival analysis was performed as previously described (Bailey et al., 2016). Statistical
analyses were carried out in either GraphPad Prism 8 (version 8.3.0) or R (version 3.6.1).
DATA AND CODE AVAILABILITY
Human pancreatic cancer gene expression and genotyping data can be found at the Gene Expression Omnibus Repository (GEO)
accession number: GSE36924 and GSE49149. Human pancreatic cancer PDCL alignments, somatic variant calls, annotations and
RNA-seq datasets are available at https://dcc.icgc.org/. ATAC-seq sequencing data from patient derived cell lines can be found at
BioProject: PRJNA630992. Original data for all datasets in this paper is available at Mendeley Data :https://doi.org/10.17632/
74s7crj7xj.1. All software packages used are publicly available through commercial vendors.Cell Reports 31, 107625, May 12, 2020 e10
